How to buy Lipocine stock | $1.32

Lipocine Inc is a biotechnology business based in the US. Lipocine shares (LPCN) are listed on the NASDAQ and all prices are listed in US Dollars. Lipocine employs 12 staff and has a market cap (total outstanding shares value) of USD$108.4 million.

How to buy shares in Lipocine

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Lipocine. Find the stock by name or ticker symbol: LPCN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Lipocine reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$1.32, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Lipocine, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Lipocine. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Lipocine share price

Use our graph to track the performance of LPCN stocks over time.

Lipocine shares at a glance

• Key figures

Information last updated 2020-12-07.

Latest market close	USD$1.32
52-week range	USD$0.301 - USD$2.39
50-day moving average	USD$1.4185
200-day moving average	USD$1.3956
Wall St. target price	USD$3
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.551

Buy Lipocine shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Lipocine stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Lipocine Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lipocine price performance over time

Historical closes compared with the close of $1.32 from 2020-12-09

1 week (2021-01-12)	N/A
1 month (2020-12-23)	-6.38%
3 months (2020-10-19)	N/A
6 months (2020-07-19)	N/A

1 year (2020-01-19)	N/A
2 years (2019-01-19)	N/A
3 years (2018-01-19)	N/A
5 years (2016-01-19)	N/A

Lipocine financials

Gross profit TTM	USD$-5,053,695
Return on assets TTM	-49.42%
Return on equity TTM	-179.39%
Profit margin	0%
Book value	$0.221
Market capitalisation	USD$108.4 million

TTM: trailing 12 months

Shorting Lipocine shares

There are currently 4.0 million Lipocine shares held short by investors – that's known as Lipocine's "short interest". This figure is 0.8% down from 4.0 million last month.

There are a few different ways that this level of interest in shorting Lipocine shares can be evaluated.

Lipocine's "short interest ratio" (SIR)

Lipocine's "short interest ratio" (SIR) is the quantity of Lipocine shares currently shorted divided by the average quantity of Lipocine shares traded daily (recently around 918123.90804598). Lipocine's SIR currently stands at 4.35. In other words for every 100,000 Lipocine shares traded daily on the market, roughly 4350 shares are currently held short.

However Lipocine's short interest can also be evaluated against the total number of Lipocine shares, or, against the total number of tradable Lipocine shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lipocine's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Lipocine shares in existence, roughly 60 shares are currently held short) or 0.0623% of the tradable shares (for every 100,000 tradable Lipocine shares, roughly 62 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lipocine.

Find out more about how you can short Lipocine stock.

Lipocine share dividends

We're not expecting Lipocine to pay a dividend over the next 12 months.

Have Lipocine's shares ever split?

Lipocine's shares were split on a 1:100 basis on 25 July 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lipocine shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Lipocine shares which in turn could have impacted Lipocine's share price.

Lipocine share price volatility

Over the last 12 months, Lipocine's shares have ranged in value from as little as $0.301 up to $2.39. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lipocine's is 0.8016. This would suggest that Lipocine's shares are less volatile than average (for this exchange).

Lipocine overview

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase 2b testing; LPCN 1148, an oral prodrug of bioidentical testosterone for the treatment of non-alcoholic steatohepatitis cirrhosis (NASH); LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase 2 Clinical trial for the treatment of NASH. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Frequently asked questions

• What percentage of Lipocine is owned by insiders or institutions?

  Currently 2.698% of Lipocine shares are held by insiders and 11.034% by institutions.

• How many people work for Lipocine?

  Latest data suggests 12 work at Lipocine.

• When does the fiscal year end for Lipocine?

  Lipocine's fiscal year ends in December.

• Where is Lipocine based?

  Lipocine's address is: 675 Arapeen Drive, Salt Lake City, UT, United States, 84108

• What is Lipocine's ISIN number?

  Lipocine's international securities identification number is: US53630X1046

• What is Lipocine's CUSIP number?

  Lipocine's Committee on Uniform Securities Identification Procedures number is: 53630X104